<VariationArchive VariationID="863830" VariationName="NM_000203.5(IDUA):c.398_403del (p.Met133_Gly134del)" VariationType="Deletion" Accession="VCV000863830" Version="14" RecordType="classified" NumberOfSubmissions="4" NumberOfSubmitters="4" DateLastUpdated="2024-07-15" DateCreated="2020-04-15" MostRecentSubmission="2024-02-14">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="828630" VariationID="863830">
      <GeneList>
        <Gene Symbol="IDUA" FullName="alpha-L-iduronidase" GeneID="3425" HGNC_ID="HGNC:5391" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>4p16.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="4" Accession="NC_000004.12" start="986997" stop="1008351" display_start="986997" display_stop="1008351" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="4" Accession="NC_000004.11" start="980784" stop="998316" display_start="980784" display_stop="998316" Strand="+" />
          </Location>
          <OMIM>252800</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000203.5(IDUA):c.398_403del (p.Met133_Gly134del)</Name>
      <CanonicalSPDI>NC_000004.12:1000892:ATGGGCA:A</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>4p16.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="4" Accession="NC_000004.12" start="1000893" stop="1000898" display_start="1000893" display_stop="1000898" variantLength="6" positionVCF="1000892" referenceAlleleVCF="GATGGGC" alternateAlleleVCF="G" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="4" Accession="NC_000004.11" start="994681" stop="994686" display_start="994681" display_stop="994686" variantLength="6" positionVCF="994680" referenceAlleleVCF="GATGGGC" alternateAlleleVCF="G" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000004.11" sequenceAccession="NC_000004" sequenceVersion="11" change="g.994682_994687del" Assembly="GRCh37">
            <Expression>NC_000004.11:g.994682_994687del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000004.12" sequenceAccession="NC_000004" sequenceVersion="12" change="g.1000894_1000899del" Assembly="GRCh38">
            <Expression>NC_000004.12:g.1000894_1000899del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008103.1" sequenceAccession="NG_008103" sequenceVersion="1" change="g.18898_18903del">
            <Expression>NG_008103.1:g.18898_18903del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000203.5" sequenceAccession="NM_000203" sequenceVersion="5" change="c.398_403del" MANESelect="true">
            <Expression>NM_000203.5:c.398_403del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000194.2" sequenceAccession="NP_000194" sequenceVersion="2" change="p.Met133_Gly134del">
            <Expression>NP_000194.2:p.Met133_Gly134del</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001822" Type="inframe_deletion" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001363576.1" sequenceAccession="NM_001363576" sequenceVersion="1" change="c.2_7del">
            <Expression>NM_001363576.1:c.2_7del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001350505.1" sequenceAccession="NP_001350505" sequenceVersion="1" change="p.Met1_Gly2del">
            <Expression>NP_001350505.1:p.Met1_Gly2del</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001822" Type="inframe_deletion" DB="SO" />
          <MolecularConsequence ID="SO:0001582" Type="initiator_codon_variant" DB="SO" />
        </HGVS>
        <HGVS Type="non-coding">
          <NucleotideExpression sequenceAccessionVersion="NR_110313.1" sequenceAccession="NR_110313" sequenceVersion="1" change="n.486_491del">
            <Expression>NR_110313.1:n.486_491del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001619" Type="non-coding transcript variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_1277" sequenceAccession="LRG_1277">
            <Expression>LRG_1277:g.18898_18903del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_1277t1" sequenceAccession="LRG_1277t1">
            <Expression>LRG_1277t1:c.398_403del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_1277p1" sequenceAccession="LRG_1277p1" change="p.Met133_Gly134del">
            <Expression>LRG_1277p1:p.Met133_Gly134del</Expression>
          </ProteinExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000203.5" sequenceAccession="NM_000203" sequenceVersion="5" change="c.398_403delTGGGCA" MANESelect="true">
            <Expression>NM_000203.5:c.398_403delTGGGCA</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="774605197" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000203.5(IDUA):c.398_403del (p.Met133_Gly134del) AND Mucopolysaccharidosis type 1" Accession="RCV001070890" Version="7">
        <ClassifiedConditionList TraitSetID="22506">
          <ClassifiedCondition DB="MedGen" ID="C0023786">Mucopolysaccharidosis type 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-10-22" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000203.5(IDUA):c.398_403del (p.Met133_Gly134del) AND Hurler syndrome" Accession="RCV001374702" Version="1">
        <ClassifiedConditionList TraitSetID="3230">
          <ClassifiedCondition DB="MedGen" ID="C0086795">Hurler syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2019-12-18" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000203.5(IDUA):c.398_403del (p.Met133_Gly134del) AND multiple conditions" Accession="RCV002497481" Version="1">
        <ClassifiedConditionList TraitSetID="10337">
          <ClassifiedCondition DB="MedGen" ID="C0086795">Hurler syndrome</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0086431">Mucopolysaccharidosis, MPS-I-H/S</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0026708">Mucopolysaccharidosis, MPS-I-S</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-12-03" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-10-22" NumberOfSubmissions="4" NumberOfSubmitters="4" DateCreated="2020-04-15" MostRecentSubmission="2024-02-14">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">12203999</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21394825</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">28752568</ID>
        </Citation>
        <DescriptionHistory Dated="2022-05-15">
          <Description>Likely pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="3230" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5271" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">MUCOPOLYSACCHARIDOSIS TYPE IH</ElementValue>
                <XRef Type="MIM" ID="607014" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hurler syndrome</ElementValue>
                <XRef ID="MONDO:0011758" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gargoylism, Hurler Syndrome</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">MPS1-H</ElementValue>
                <XRef Type="MIM" ID="607014" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">MPS I H</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="12559" />
                <XRef ID="12559" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Mucopolysaccharidosis type I (MPS I) is a progressive multisystem disorder with features ranging over a continuum of severity. While affected individuals have traditionally been classified as having one of three MPS I syndromes (Hurler syndrome, Hurler-Scheie syndrome, or Scheie syndrome), no easily measurable biochemical differences have been identified and the clinical findings overlap. Affected individuals are best described as having either a phenotype consistent with either severe (Hurler syndrome) or attenuated MPS I, a distinction that influences therapeutic options. Severe MPS I. Infants appear normal at birth. Typical early manifestations are nonspecific (e.g., umbilical or inguinal hernia, frequent upper respiratory tract infections before age 1 year). Coarsening of the facial features may not become apparent until after age one year. Gibbus deformity of the lower spine is common and often noted within the first year. Progressive skeletal dysplasia (dysostosis multiplex) involving all bones is universal, as is progressive arthropathy involving most joints. By age three years, linear growth decreases. Intellectual disability is progressive and profound but may not be readily apparent in the first year of life. Progressive cardiorespiratory involvement, hearing loss, and corneal clouding are common. Without treatment, death (typically from cardiorespiratory failure) usually occurs within the first ten years of life. Attenuated MPS I. Clinical onset is usually between ages three and ten years. The severity and rate of disease progression range from serious life-threatening complications leading to death in the second to third decade, to a normal life span complicated by significant disability from progressive joint manifestations and cardiorespiratory disease. While some individuals have no neurologic involvement and psychomotor development may be normal in early childhood, learning disabilities and psychiatric manifestations can be present later in life. Hearing loss, cardiac valvular disease, respiratory involvement, and corneal clouding are common.</Attribute>
                <XRef ID="NBK1162" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301341</ID>
                <ID Source="BookShelf">NBK1162</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/MPSI-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, alpha-L-iduronidase deficiency with or without glycosaminoglycan (GAG) accumulation, Mucopolysaccharidosis Type 1 (MPS I), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/MPSI-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, MPS I: Decreased Alpha-L-Iduronidase; Elevated Dermatan and Heparan Sulfates, 2023</CitationText>
              </Citation>
              <XRef ID="93473" DB="Orphanet" />
              <XRef ID="C0086795" DB="MedGen" />
              <XRef ID="MONDO:0011758" DB="MONDO" />
              <XRef Type="MIM" ID="607014" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="10337" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3695" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">MUCOPOLYSACCHARIDOSIS TYPE IS</ElementValue>
                <XRef Type="MIM" ID="607016" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">MPS V</ElementValue>
                <XRef Type="MIM" ID="607016" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">MUCOPOLYSACCHARIDOSIS TYPE V</ElementValue>
                <XRef Type="MIM" ID="607016" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Scheie Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Mucopolysaccharidosis, MPS-I-S</ElementValue>
                <XRef ID="Mucopolysaccharidosis%2C+MPS-I-S/8912" DB="Genetic Alliance" />
                <XRef ID="73123008" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">MPS5</ElementValue>
                <XRef Type="MIM" ID="607016" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">MPS1-S</ElementValue>
                <XRef Type="MIM" ID="607016" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Mucopolysaccharidosis type I (MPS I) is a progressive multisystem disorder with features ranging over a continuum of severity. While affected individuals have traditionally been classified as having one of three MPS I syndromes (Hurler syndrome, Hurler-Scheie syndrome, or Scheie syndrome), no easily measurable biochemical differences have been identified and the clinical findings overlap. Affected individuals are best described as having either a phenotype consistent with either severe (Hurler syndrome) or attenuated MPS I, a distinction that influences therapeutic options. Severe MPS I. Infants appear normal at birth. Typical early manifestations are nonspecific (e.g., umbilical or inguinal hernia, frequent upper respiratory tract infections before age 1 year). Coarsening of the facial features may not become apparent until after age one year. Gibbus deformity of the lower spine is common and often noted within the first year. Progressive skeletal dysplasia (dysostosis multiplex) involving all bones is universal, as is progressive arthropathy involving most joints. By age three years, linear growth decreases. Intellectual disability is progressive and profound but may not be readily apparent in the first year of life. Progressive cardiorespiratory involvement, hearing loss, and corneal clouding are common. Without treatment, death (typically from cardiorespiratory failure) usually occurs within the first ten years of life. Attenuated MPS I. Clinical onset is usually between ages three and ten years. The severity and rate of disease progression range from serious life-threatening complications leading to death in the second to third decade, to a normal life span complicated by significant disability from progressive joint manifestations and cardiorespiratory disease. While some individuals have no neurologic involvement and psychomotor development may be normal in early childhood, learning disabilities and psychiatric manifestations can be present later in life. Hearing loss, cardiac valvular disease, respiratory involvement, and corneal clouding are common.</Attribute>
                <XRef ID="NBK1162" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="12561" />
                <XRef ID="12561" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301341</ID>
                <ID Source="BookShelf">NBK1162</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/MPSI-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, alpha-L-iduronidase deficiency with or without glycosaminoglycan (GAG) accumulation, Mucopolysaccharidosis Type 1 (MPS I), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/MPSI-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, MPS I: Decreased Alpha-L-Iduronidase; Elevated Dermatan and Heparan Sulfates, 2023</CitationText>
              </Citation>
              <XRef ID="93474" DB="Orphanet" />
              <XRef ID="C0026708" DB="MedGen" />
              <XRef ID="MONDO:0011760" DB="MONDO" />
              <XRef Type="MIM" ID="607016" DB="OMIM" />
            </Trait>
            <Trait ID="5271" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">MUCOPOLYSACCHARIDOSIS TYPE IH</ElementValue>
                <XRef Type="MIM" ID="607014" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hurler syndrome</ElementValue>
                <XRef ID="MONDO:0011758" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gargoylism, Hurler Syndrome</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">MPS1-H</ElementValue>
                <XRef Type="MIM" ID="607014" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">MPS I H</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="12559" />
                <XRef ID="12559" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Mucopolysaccharidosis type I (MPS I) is a progressive multisystem disorder with features ranging over a continuum of severity. While affected individuals have traditionally been classified as having one of three MPS I syndromes (Hurler syndrome, Hurler-Scheie syndrome, or Scheie syndrome), no easily measurable biochemical differences have been identified and the clinical findings overlap. Affected individuals are best described as having either a phenotype consistent with either severe (Hurler syndrome) or attenuated MPS I, a distinction that influences therapeutic options. Severe MPS I. Infants appear normal at birth. Typical early manifestations are nonspecific (e.g., umbilical or inguinal hernia, frequent upper respiratory tract infections before age 1 year). Coarsening of the facial features may not become apparent until after age one year. Gibbus deformity of the lower spine is common and often noted within the first year. Progressive skeletal dysplasia (dysostosis multiplex) involving all bones is universal, as is progressive arthropathy involving most joints. By age three years, linear growth decreases. Intellectual disability is progressive and profound but may not be readily apparent in the first year of life. Progressive cardiorespiratory involvement, hearing loss, and corneal clouding are common. Without treatment, death (typically from cardiorespiratory failure) usually occurs within the first ten years of life. Attenuated MPS I. Clinical onset is usually between ages three and ten years. The severity and rate of disease progression range from serious life-threatening complications leading to death in the second to third decade, to a normal life span complicated by significant disability from progressive joint manifestations and cardiorespiratory disease. While some individuals have no neurologic involvement and psychomotor development may be normal in early childhood, learning disabilities and psychiatric manifestations can be present later in life. Hearing loss, cardiac valvular disease, respiratory involvement, and corneal clouding are common.</Attribute>
                <XRef ID="NBK1162" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301341</ID>
                <ID Source="BookShelf">NBK1162</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/MPSI-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, alpha-L-iduronidase deficiency with or without glycosaminoglycan (GAG) accumulation, Mucopolysaccharidosis Type 1 (MPS I), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/MPSI-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, MPS I: Decreased Alpha-L-Iduronidase; Elevated Dermatan and Heparan Sulfates, 2023</CitationText>
              </Citation>
              <XRef ID="93473" DB="Orphanet" />
              <XRef ID="C0086795" DB="MedGen" />
              <XRef ID="MONDO:0011758" DB="MONDO" />
              <XRef Type="MIM" ID="607014" DB="OMIM" />
            </Trait>
            <Trait ID="5272" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">MUCOPOLYSACCHARIDOSIS TYPE IH/S</ElementValue>
                <XRef Type="MIM" ID="607015" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Mucopolysaccharidosis, MPS-I-H/S</ElementValue>
                <XRef ID="Mucopolysaccharidosis%2C+MPS-I-H-S/8911" DB="Genetic Alliance" />
                <XRef ID="26745009" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">MPS1-HS</ElementValue>
                <XRef Type="MIM" ID="607015" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="12560" />
                <XRef ID="12560" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Mucopolysaccharidosis type I (MPS I) is a progressive multisystem disorder with features ranging over a continuum of severity. While affected individuals have traditionally been classified as having one of three MPS I syndromes (Hurler syndrome, Hurler-Scheie syndrome, or Scheie syndrome), no easily measurable biochemical differences have been identified and the clinical findings overlap. Affected individuals are best described as having either a phenotype consistent with either severe (Hurler syndrome) or attenuated MPS I, a distinction that influences therapeutic options. Severe MPS I. Infants appear normal at birth. Typical early manifestations are nonspecific (e.g., umbilical or inguinal hernia, frequent upper respiratory tract infections before age 1 year). Coarsening of the facial features may not become apparent until after age one year. Gibbus deformity of the lower spine is common and often noted within the first year. Progressive skeletal dysplasia (dysostosis multiplex) involving all bones is universal, as is progressive arthropathy involving most joints. By age three years, linear growth decreases. Intellectual disability is progressive and profound but may not be readily apparent in the first year of life. Progressive cardiorespiratory involvement, hearing loss, and corneal clouding are common. Without treatment, death (typically from cardiorespiratory failure) usually occurs within the first ten years of life. Attenuated MPS I. Clinical onset is usually between ages three and ten years. The severity and rate of disease progression range from serious life-threatening complications leading to death in the second to third decade, to a normal life span complicated by significant disability from progressive joint manifestations and cardiorespiratory disease. While some individuals have no neurologic involvement and psychomotor development may be normal in early childhood, learning disabilities and psychiatric manifestations can be present later in life. Hearing loss, cardiac valvular disease, respiratory involvement, and corneal clouding are common.</Attribute>
                <XRef ID="NBK1162" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301341</ID>
                <ID Source="BookShelf">NBK1162</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/MPSI-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, alpha-L-iduronidase deficiency with or without glycosaminoglycan (GAG) accumulation, Mucopolysaccharidosis Type 1 (MPS I), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/MPSI-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, MPS I: Decreased Alpha-L-Iduronidase; Elevated Dermatan and Heparan Sulfates, 2023</CitationText>
              </Citation>
              <XRef ID="93476" DB="Orphanet" />
              <XRef ID="C0086431" DB="MedGen" />
              <XRef ID="MONDO:0011759" DB="MONDO" />
              <XRef Type="MIM" ID="607015" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="22506" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="7856" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Mucopolysaccharidosis type 1</ElementValue>
                <XRef ID="MONDO:0001586" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type I</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MPS 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Attenuated MPS I (subtype)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Severe MPS I (subtype)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hurler syndrome (former subtype)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hurler-Scheie syndrome (former subtype)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Scheie syndrome (former subtype; formerly known as Mucopoly-saccharidosis type V)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpha-L-Iduronidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">IDUA deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MPS I</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MPS1</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10335" />
                <XRef ID="10335" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Mucopolysaccharidosis type I (MPS I) is a progressive multisystem disorder with features ranging over a continuum of severity. While affected individuals have traditionally been classified as having one of three MPS I syndromes (Hurler syndrome, Hurler-Scheie syndrome, or Scheie syndrome), no easily measurable biochemical differences have been identified and the clinical findings overlap. Affected individuals are best described as having either a phenotype consistent with either severe (Hurler syndrome) or attenuated MPS I, a distinction that influences therapeutic options. Severe MPS I. Infants appear normal at birth. Typical early manifestations are nonspecific (e.g., umbilical or inguinal hernia, frequent upper respiratory tract infections before age 1 year). Coarsening of the facial features may not become apparent until after age one year. Gibbus deformity of the lower spine is common and often noted within the first year. Progressive skeletal dysplasia (dysostosis multiplex) involving all bones is universal, as is progressive arthropathy involving most joints. By age three years, linear growth decreases. Intellectual disability is progressive and profound but may not be readily apparent in the first year of life. Progressive cardiorespiratory involvement, hearing loss, and corneal clouding are common. Without treatment, death (typically from cardiorespiratory failure) usually occurs within the first ten years of life. Attenuated MPS I. Clinical onset is usually between ages three and ten years. The severity and rate of disease progression range from serious life-threatening complications leading to death in the second to third decade, to a normal life span complicated by significant disability from progressive joint manifestations and cardiorespiratory disease. While some individuals have no neurologic involvement and psychomotor development may be normal in early childhood, learning disabilities and psychiatric manifestations can be present later in life. Hearing loss, cardiac valvular disease, respiratory involvement, and corneal clouding are common.</Attribute>
                <XRef ID="NBK1162" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301341</ID>
                <ID Source="BookShelf">NBK1162</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/MPSI-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, alpha-L-iduronidase deficiency with or without glycosaminoglycan (GAG) accumulation, Mucopolysaccharidosis Type 1 (MPS I), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/MPSI-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, MPS I: Decreased Alpha-L-Iduronidase; Elevated Dermatan and Heparan Sulfates, 2023</CitationText>
              </Citation>
              <XRef ID="579" DB="Orphanet" />
              <XRef ID="C0023786" DB="MedGen" />
              <XRef ID="MONDO:0001586" DB="MONDO" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="3094533" SubmissionDate="2021-04-20" DateLastUpdated="2023-09-03" DateCreated="2021-04-23">
        <ClinVarSubmissionID localKey="SUB9435999" submittedAssembly="GRCh37" title="SUB9435999" />
        <ClinVarAccession Accession="SCV001571610" DateUpdated="2023-09-03" DateCreated="2021-04-23" Type="SCV" Version="2" SubmitterName="NxGen MDx" OrgID="507143" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-12-18">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Citation Type="general">
            <ID Source="PubMed">12203999</ID>
          </Citation>
          <Citation Type="general">
            <ID Source="PubMed">21394825</ID>
          </Citation>
          <Citation Type="general">
            <ID Source="PubMed">28752568</ID>
          </Citation>
          <Comment>This in-frame deletion (c.398_403del) in exon 4 of IDUA results in the loss of two amino acids (p.Met133_Gly134del) (PM4). This variant has a low allele frequency in GnomAD exomes (PM2) and was first reported in Venturi et al PMID 12203999 with an unknown phenotype and later in Bertola et al. PMID 21394825 and Ghosh et al. PMID: 28752568 associated with mucopolysaccharidosis type I. This variant may result in a start loss in a non-canonical transcript (NM_001363576.1), though the clinical relevance of this transcript is unknown. We interpret c.398_403del to be likely pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation Type="general">
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="IDUA">
              <Name>alpha-L-iduronidase</Name>
            </Gene>
          </GeneList>
          <VariantType>Variation</VariantType>
          <XRefList>
            <XRef DB="dbSNP" ID="rs774605197" />
          </XRefList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000203.5:c.398_403delTGGGCA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="607014" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB9435999</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4068463" SubmissionDate="2022-02-09" DateLastUpdated="2023-09-03" DateCreated="2022-04-23">
        <ClinVarSubmissionID localKey="NM_000203.5:c.398_403del|Mucopolysaccharidosis type I" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002075284" DateUpdated="2023-09-03" DateCreated="2022-04-23" Type="SCV" Version="2" SubmitterName="Natera, Inc." OrgID="500034" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-08-25">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000203.5:c.398_403del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Mucopolysaccharidosis type I</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10993736</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5461510" SubmissionDate="2022-12-13" DateLastUpdated="2023-09-03" DateCreated="2022-12-31">
        <ClinVarSubmissionID localKey="NM_000203.5:c.398_403del|OMIM:607014;607015;607016" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002807692" DateUpdated="2023-09-03" DateCreated="2022-12-31" Type="SCV" Version="2" SubmitterName="Fulgent Genetics, Fulgent Genetics" OrgID="500105" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-12-03">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000203.5:c.398_403del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="TraitChoice">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="607014" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="607015" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="607016" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12390657</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2401832" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2020-04-15">
        <ClinVarSubmissionID localKey="4848632|MedGen:C0023786" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001236169" DateUpdated="2024-02-14" DateCreated="2020-04-15" Type="SCV" Version="6" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-10-22">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">12203999</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21394825</ID>
          </Citation>
          <Comment>This variant, c.398_403del, results in the deletion of 2 amino acid(s) of the IDUA protein (p.Met133_Gly134del), but otherwise preserves the integrity of the reading frame. This variant is present in population databases (rs774605197, gnomAD 0.006%). This variant has been observed in individual(s) with mucopolysaccharidosis type I (PMID: 12203999, 21394825; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is also known as 486-491del6. ClinVar contains an entry for this variant (Variation ID: 863830). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="IDUA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000004.11:g.994681_994686del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0023786" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="2401832" TraitType="Disease" MappingType="XRef" MappingValue="C0023786" MappingRef="MedGen">
        <MedGen CUI="C0023786" Name="Mucopolysaccharidosis type 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4068463" TraitType="Disease" MappingType="Name" MappingValue="Mucopolysaccharidosis type I" MappingRef="Preferred">
        <MedGen CUI="C0023786" Name="Mucopolysaccharidosis type 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3094533" TraitType="Disease" MappingType="XRef" MappingValue="607014" MappingRef="OMIM">
        <MedGen CUI="C0086795" Name="Hurler syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5461510" TraitType="Disease" MappingType="XRef" MappingValue="607014" MappingRef="OMIM">
        <MedGen CUI="C0086795" Name="Hurler syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5461510" TraitType="Disease" MappingType="XRef" MappingValue="607016" MappingRef="OMIM">
        <MedGen CUI="C0026708" Name="Mucopolysaccharidosis, MPS-I-S" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5461510" TraitType="Disease" MappingType="XRef" MappingValue="607015" MappingRef="OMIM">
        <MedGen CUI="C0086431" Name="Mucopolysaccharidosis, MPS-I-H/S" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

